Analysed ZENAS BIOPHARMA INC (ZBIO:NASDAQ) News Sources
IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading
07-05-2026
yahoo.com
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
13-05-2026
yahoo.com
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
13-05-2026
yahoo.com
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss
13-05-2026
yahoo.com
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18-05-2026
yahoo.com
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
19-05-2026
yahoo.com
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
28-05-2026
yahoo.com
A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness
01-06-2026
yahoo.com
What is the current price of ZENAS BIOPHARMA INC (ZBIO:NASDAQ)?
The current price of ZENAS BIOPHARMA INC (ZBIO:NASDAQ) is $17.13.
ZENAS BIOPHARMA INC (ZBIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ZENAS BIOPHARMA INC (ZBIO:NASDAQ) since the previous trading day is $-1.04.
ZENAS BIOPHARMA INC (ZBIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ZENAS BIOPHARMA INC (ZBIO:NASDAQ) since the previous trading day is -5.7237%.
What is the most recent average sentiment score for ZENAS BIOPHARMA INC (ZBIO:NASDAQ)?
The most recent average sentiment score for ZENAS BIOPHARMA INC (ZBIO:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for ZENAS BIOPHARMA INC (ZBIO:NASDAQ)?
The most recent sentiment for ZENAS BIOPHARMA INC (ZBIO:NASDAQ) is .
SEC-8K** Filing Available For ZENAS BIOPHARMA INC (ZBIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.